# Vir Biotechnology, Inc. (VIR) FY2026 Q2 P&L / Income Statement

- Company: Vir Biotechnology, Inc. (VIR)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001628280-26-053549
- Page: https://plicit.ai/financials/vir/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/vir-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 238,946,000 US dollars
- **Cost of revenue**: 0 US dollars
- **Gross profit (calculated)**: 238,946,000 US dollars
- **Operating expenses (calculated)**: 165,479,000 US dollars
- **Income (loss) from operations**: 73,467,000 US dollars
- **Total other income**: 6,792,000 US dollars
- **Income (loss) before provision for income taxes**: 80,259,000 US dollars
- **Provision for income taxes**: 179,000 US dollars
- **Net income (loss)**: 80,080,000 US dollars
- **License and collaboration revenue**: 238,935,000 US dollars
- **Grant revenue**: 11,000 US dollars
- **Other revenue**: 0 US dollars
- **Research and development**: 135,283,000 US dollars
- **Selling, general and administrative**: 30,196,000 US dollars
- **Restructuring, long-lived assets impairment and related charges, net**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.